Seroatlas · Human Serome Atlas

CYP2B6

Cytochrome P450 2B6

Also known as: CP2B6_HUMAN, CPB6, CYP2B, CYPIIB6

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P20813
Gene
CYP2B6
Ensembl
ENSG00000197408
Chromosome
19
Canonical length
491 aa
Protein class
Metabolic proteins, Plasma proteins, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Nuclear membrane,Cytosol
Secretome location
Intracellular and membrane

OverviewNCBI Gene

This gene, CYP2B6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to metabolize some xenobiotics, such as the anti-cancer drugs cyclophosphamide and ifosphamide. Transcript variants for this gene have been described; however, it has not been resolved whether these transcripts are in fact produced by this gene or by a closely related pseudogene, CYP2B7. Both the gene and the pseudogene are located in the middle of a CYP2A pseudogene found in a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

491 residues, UniProt reviewed canonical sequence.

>P20813|CYP2B6
     1  MELSVLLFLA LLTGLLLLLV QRHPNTHDRL PPGPRPLPLL GNLLQMDRRG LLKSFLRFRE
    61  KYGDVFTVHL GPRPVVMLCG VEAIREALVD KAEAFSGRGK IAMVDPFFRG YGVIFANGNR
   121  WKVLRRFSVT TMRDFGMGKR SVEERIQEEA QCLIEELRKS KGALMDPTFL FQSITANIIC
   181  SIVFGKRFHY QDQEFLKMLN LFYQTFSLIS SVFGQLFELF SGFLKYFPGA HRQVYKNLQE
   241  INAYIGHSVE KHRETLDPSA PKDLIDTYLL HMEKEKSNAH SEFSHQNLNL NTLSLFFAGT
   301  ETTSTTLRYG FLLMLKYPHV AERVYREIEQ VIGPHRPPEL HDRAKMPYTE AVIYEIQRFS
   361  DLLPMGVPHI VTQHTSFRGY IIPKDTEVFL ILSTALHDPH YFEKPDAFNP DHFLDANGAL
   421  KKTEAFIPFS LGKRICLGEG IARAELFLFF TTILQNFSMA SPVAPEDIDL TPQECGVGKI
   481  PPTYQIRFLP R

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CYP2B6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Other membrane
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.23
Highest tissue expression
550 nTPM

Expression across tissuesHPA

Tissue

  • liver: 550 nTPM
  • kidney: 14 nTPM
  • duodenum: 7.4 nTPM
  • small intestine: 7.1 nTPM
  • lung: 5.6 nTPM
  • colon: 4.7 nTPM

Single-cell type

  • hepatocytes: 1,060 nCPM
  • conjunctival goblet cells: 161 nCPM
  • enterocytes: 50 nCPM
  • proximal tubule cells: 31 nCPM
  • respiratory secretory cells: 22 nCPM
  • cholangiocytes: 20 nCPM

Immune cell

  • basophil: 0.4 nTPM
  • neutrophil: 0.3 nTPM
  • plasmacytoid DC: 0.3 nTPM
  • eosinophil: 0.2 nTPM
  • naive B-cell: 0.2 nTPM
  • classical monocyte: 0.1 nTPM

Brain region

  • cerebellum: 2 nTPM
  • white matter: 2 nTPM
  • medulla oblongata: 1.8 nTPM
  • cerebral cortex: 1.7 nTPM
  • choroid plexus: 1.6 nTPM
  • hippocampal formation: 1.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.24
gnomAD pLI
0
gnomAD missense Z
-0.98
DepMap mean gene effect
0.04
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CYP2B6 as an antibody target. Whether an autoantibody or antibody against CYP2B6 could matter depends on whether native CYP2B6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CYP2B6 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label CYP2B6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/CYP2B6. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...